New drug HEC89736 tested in blood cancer patients – but trial stopped early
NCT ID NCT04865458
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental drug called HEC89736 in people with B-cell blood cancers that had returned or stopped responding to treatment. The study aimed to check the drug's safety and how the body processes it. Only 5 people took part before the trial was terminated, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HEC89736 (an experimental oral drug)
- What this could lead to
- If it works, this could point toward a new treatment option for people with certain blood cancers that have come back or not responded to other therapies.
- What could go wrong
- This was a very early, small trial (only 5 people) that was terminated early, so we have very little data. The drug may not be effective or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY B-CELL HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, China